Methylnaltrexone
A peripherally acting opioid antagonist used to relieve opioid-induced constipation in patients with chronic non-cancer pain or advanced illness. It blocks opioid receptors in the gut without affecting pain control.
الوزن الجزيئي
356,4000 g/mol
LogP
1,60
TPSA
66,80 Ų
قاعدة ليبينسكي للخمسة
ناجح
المجالات العلاجية
آلية العمل
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …
البنية ثنائية الأبعاد
Cite this structure
Embed this structure
SMILES
C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
InChI
InChI=1S/C21H25NO4/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13/h4-5,12,16,19,25H,2-3,6-11H2,1H3/p+1/t16-,19+,20+,21-,22?/m1/s1
Molecular Formula
C21H26NO4+
HBD / HBA
2 / 4
الروابط القابلة للدوران
2
الذرات الثقيلة
26
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
الأسئلة الشائعة
A peripherally acting opioid antagonist used to relieve opioid-induced constipation in patients with chronic non-cancer pain or advanced illness. It blocks opioid receptors in the gut without affecting pain control.
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Yes, Methylnaltrexone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1186579. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5361918. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="methylnaltrexone"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/methylnaltrexone/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/methylnaltrexone/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/methylnaltrexone/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="methylnaltrexone"></drugfyi-drug>